Gemma

Gemma is a binary hemostatic powder developed by TRIZ Biopharma Innovations for the control of life-threatening bleeding in traumatic, surgical, and battlefield settings. Designed as a topical application, it is composed of natural semisynthetic components that are biodegradable and biocompatible, eliminating the need for removal from the wound site. Unlike traditional agents that may cause tissue irritation or burns, Gemma utilizes a 'binary effect' to achieve rapid hemostasis without causing necrosis. It has been filed as a medical device under the FDA's 510(k) pathway and is characterized by its use of inexpensive raw materials and strong tissue compatibility.

Brand names

Gemma

Other names

Gemma hemostatic powder